English– tag –
-
Dr. Kiyoshi Takayama, NBHL Founder and President will make a pitch at the JETRO event in Boston.
Dr. Kiyoshi Takayama, NBHL Founder and President will make a pitch introducin... -
NBHL will participate in Biotech Showcase (January 9-11 in San Francisco).
Dr. Kiyoshi Takayama, NBHL Founder and President will make a presentation int... -
Election of Director and Auditor of the Company
We are pleased to announce that at the Extraordinary General Meeting of Share... -
NBHL will participate in BioCentury-BayHelix East-West Biopharma Summit 2022 (November 14-16 in San Francisco, 17-18 Virtual).
Dr. Kiyoshi Takayama, NBHL Founder and President will make a presentation int... -
Dr. Hiroki Shirai, former executive fellow at Astellas Pharma Inc. (currently affiliated at RIKEN), appointed as our Science Advisor
Accelerating theoretical R&D of therapeutic functional antibodies through... -
NBHL will participate in Festival of Biologics in Switzerland (November 2-4, 2022).
NBHL will participate in Festival of Biologics in Switzerland (November 2-4, ... -
NBHL will participate in BIO-Europe in Germany and Digital (October-November 2022).
NBHL will participate in BIO-Europe in Germany (October 24-26, 2022) and Digi... -
Kiyoshi Takayama, our President, will lecture at Discovery on TARGET (October 19, 2022) (Boston, USA & Virtual)
Kiyoshi Takayama, our President, will give a lecture at Discovery on TARGET a... -
Completion of the Series C funding to advance pipeline of novel GPCR antibodies
NBHL has completed 7.64 million USD of the Series C funding to advance pipeli... -
Announcement of a grant of patent for innovative new high-throughput single-cell analysis technology in US 2022.03.29.
We are pleased to inform you that the patent we applied for the new drug cand...
